Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429669 | 0.98 | ELANE (0.79) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| Acetic Acid Phenyl Ester SCHEMBL5189342 | 0.94 | MAPT (0.67) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL16429666 | 0.94 | ELANE (0.72) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL6054677 | 0.94 | ELANE (0.72) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL10863256 | 0.93 | ELANE (0.71) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL9760675 | 0.90 | ELANE (0.64) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL8850878 | 0.90 | ELANE (0.64) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL725405 | 0.89 | PARP10 (0.77) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL7880523 | 0.89 | MAPT (0.75) | ELANEMAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL9507152 | 0.89 | ELANE (0.76) | ELANEMAPTTDP1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206151-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141662-A1 | Method Of Preparing Fused Ring Indeno Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029565-B1 | Fused ring indeno compounds for preparation of photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141662-A1 | Method Of Preparing Fused Ring Indeno Compounds | INHA, INTS9, CA9 | ELANE 1528/4885MAPT 3458/4885TDP1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.